Loading clinical trials...
Loading clinical trials...
Phase II Study Assessing Safety and Clinical Activity of the Combination of ASTX727 With Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Conditions
Interventions
Dasatinib
Decitabine and Cedazuridine
Locations
1
United States
M D Anderson Cancer Center
Houston, Texas, United States
Start Date
October 21, 2021
Primary Completion Date
October 30, 2026
Completion Date
October 30, 2026
Last Updated
February 18, 2026
NCT02997761
NCT02689440
NCT04722848
NCT07356960
NCT00254423
NCT03698552
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions